ArticlePloS one2025
COVID-19 breakthrough infections during the circulation of Delta and Omicron variants in Tirana, Albania, April 2021-March 2022.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 breakthrough cases raised crucial questions about vaccine effectiveness, implications for public health, and the dynamics of viral transmission. We described vaccine breakthrough infections in Tirana during the Delta (01/07/2021-12/15/2021) and Omicron (16/12/2021-31/03/2022) periods, to better inform mitigation and vaccination strategies.
methodsWe extracted data from 01/04/2021-31/03/2022 (study period) from two systems: the Albanian infectious disease surveillance system, and the national vaccination database. We defined a COVID-19 case as a resident of Tirana who tested (RT-PCR/antigen) positive for SARS-CoV-2 on a respiratory specimen. We defined vaccine breakthrough infection as having a COVID-19 positive specimen collected ≥14 days after the primary series of vaccines (2 doses). We calculated risk of breakthrough infection using the total number of fully vaccinated individuals as denominator and risk ratios (RR) using binomial regression.
resultsDuring the study period, 23,875 cases were reported in Tirana; 36% (291,445/800,000) individuals were fully vaccinated and among those, 9,156 (3.1%) breakthrough infections were detected. The median time from vaccination to breakthrough infection was 149 (IQR:102-209) days. The risk of breakthrough infection was higher in 0-39-year-olds (RR = 3.01;95%CI = 2.78-3.27) and during the Omicron period (RR = 32; 95%CI = 30.00-34.91). Those receiving Gam-COVID ((RR = 1.64;95%CI = 1.39-2.02), ChAdOx1-S/Vaxzervria (RR = 1.56;95%CI = 1.48-1.65), or BNT162b2-Comirnaty (RR = 1.36;95%CI = 1.31-1.41) had a higher risk of breakthrough infection compared with those vaccinated with CoronaVac.
conclusionsIncidence of COVID-19 breakthrough infection was significantly higher during the Omicron period and among younger individuals in Tirana. The substantially elevated risk associated with Omicron variant breakthrough infection and the decline in infection protection after a 5-month period, warrants close monitoring and rapid adaptation of vaccination strategies, including promoting booster vaccination to reduce breakthrough infections in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.